Pozen Inc.'s injected migraine drug, MT300, achieved its primary endpoint - sustained relief of pain - in its second pivotal trial and, although the drug did not do as well meeting secondary endpoints during the two hours after dosing, it showed statistical significance in providing relief of those symptoms on a sustained basis. (Bioworld Today)

IDEC Pharmaceuticals Corp. licensed a small-molecule cancer drug from Japan and the company's chief financial officer resigned, but analysts seemed just as interested - if not more - in a third bit of news not formally disclosed by the company: an abstract showing how well Rituxan (rituximab) worked against rheumatoid arthritis in Phase II trials. (BioWorld Today)